Drugs / Vicriviroc
Vicriviroc
also known as
SCH 417690 · VCV · MK-4176 · MK-7690 · SCH-417690 FREE BASE · SCH-D · Schering D · VICRIVIROC MALEATE
Small molecule targets CCR5 via inhibition
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02419456 | Jun 2015 → Mar 2016 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00632073 | Mar 2008 → Jul 2009 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00766597 | Aug 2009 → Jul 2010 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT03631407 | Sep 2018 → Jun 2021 | colorectal neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00551018 | Dec 2007 → May 2010 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00551330 | Sep 2007 → Feb 2010 | AIDS | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00243230 | Sep 2005 → Oct 2007 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00686829 | Jun 2005 → Oct 2010 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00082498 | May 2004 → Dec 2005 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT00523211 | Jul 2007 → Jun 2009 | AIDS | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00474370 | May 2007 → Aug 2009 | AIDS | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00243568 | Sep 2005 → ? | AIDS | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vicriviroc | “Contains 91 mg of vicriviroc (MK-4176) and 10 mg of MK-2048.” NCT02419456 ↗ |
| Known as | MK-4176 | “Contains 91 mg of vicriviroc (MK-4176) and 10 mg of MK-2048.” NCT02419456 ↗ |
| Known as | MK-7690 | ChEMBL registry synonym — accepted as the source's own label CHEMBL82301 ↗ |
| Known as | SCH 417690 | “This study will test the safety and effectiveness of three different doses of vicriviroc (formerly known as Schering D, SCH-D, or SCH 417690) in HIV infected patients.” NCT00082498 ↗1“Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Subjects (VICTOR-E2)” NCT00243568 ↗ |
| Known as | SCH-417690 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL82301 ↗ |
| Known as | SCH-D | “This study will test the safety and effectiveness of three different doses of vicriviroc (formerly known as Schering D, SCH-D, or SCH 417690) in HIV infected patients.” NCT00082498 ↗ |
| Known as | Schering D | “This study will test the safety and effectiveness of three different doses of vicriviroc (formerly known as Schering D, SCH-D, or SCH 417690) in HIV infected patients.” NCT00082498 ↗ |
| Known as | VCV | “The purpose of this study is to test the effectiveness and safety of Vicriviroc (VCV), an HIV entry inhibitor and CCR5 co-receptor antagonist.” NCT00766597 ↗1“The purpose of this study is to provide open-label vicriviroc (VCV) to human immunodeficiency virus (HIV) treatment-experienced participants” NCT00686829 ↗ |
| Known as | VICRIVIROC MALEATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL82301 ↗ |
| Action | Inhibit | “Vicriviroc, an investigational CCR5 antagonist, demonstrated short-term safety and antiretroviral activity.” PMID 20672447 ↗ Aug 2010 |
| Modality | Small molecule | — CHEMBL82301 ↗ |
| Route | Oral | “Vicriviroc is an oral HIV-1 entry inhibitor” NCT00082498 ↗ |
| Target | CCR5 | “targets the CCR5 receptor of T cells” NCT00082498 ↗ |